Table 1 Number of drugs and active ingredients among statins*
From: Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea
| Â | Year | 2005 | 2006 | 2007 | 2008 | 2009 |
|---|---|---|---|---|---|---|
Number of drugs | Total | 183 | 207 | 217 | 227 | 271 |
Core medicines (A) | Â | 167 | 192 | 176 | 204 | |
Exiting medicines (B) | Â | 16 | 15 | 41 | 23 | |
New entrants (C) | Â | 40 | 25 | 51 | 67 | |
   - New molecular entities |  | 0 | 0 | 0 | 1 | |
   - New medicines |  | 1 | 0 | 1 | 5 | |
   - New generic medicines |  | 9 | 13 | 37 | 29 | |
   - Others |  | 30 | 12 | 13 | 32 | |
Number of active ingredients | Total | 19 | 22 | 23 | 24 | 30 |
Core medicines (A) | Â | 19 | 22 | 23 | 24 | |
Exiting medicines (B) | Â | 6 | 4 | 8 | 6 | |
New entrants (C) | Â | 13 | 8 | 12 | 17 | |
   - New molecular entities |  | 0 | 0 | 0 | 1 | |
   - New medicines |  | 1 | 0 | 1 | 5 | |
   - New generic medicines |  | 6 | 5 | 6 | 5 | |
|  |    - Others |  | 6 | 3 | 5 | 6 |